OBJECTIVE: This study evaluates longitudinal neuropsychological performance and its association with clinical symptomatology and psychosocial outcome in individuals identified as ultra high risk (UHR) for psychosis. METHODS: Thirty-five UHR individuals completed neurocognitive, clinical, and social/role functioning assessments at baseline and, on average, 8.3 months later. RESULTS: UHR subjects showed significant cognitive deficits at baseline and 2 distinct profiles of cognitive change over time. On average, 50% demonstrated improvement in social and role functioning over the follow-up period, while the other half showed either stability or decline in functioning. Functional improvement was associated with improved processing speed and visual memory, as well as improvement in clinical symptoms over the follow-up period. In contrast, patients who did not improve functionally showed stable clinical symptoms and cognitive performance over time. CONCLUSIONS: Although the degree of neurocognitive deficit at baseline in UHR patients does not predict psychosocial outcome, the course of neurocognitive change over the first 8 months of follow-up does differentiate patients with good and poor functional outcomes.
OBJECTIVE: This study evaluates longitudinal neuropsychological performance and its association with clinical symptomatology and psychosocial outcome in individuals identified as ultra high risk (UHR) for psychosis. METHODS: Thirty-five UHR individuals completed neurocognitive, clinical, and social/role functioning assessments at baseline and, on average, 8.3 months later. RESULTS: UHR subjects showed significant cognitive deficits at baseline and 2 distinct profiles of cognitive change over time. On average, 50% demonstrated improvement in social and role functioning over the follow-up period, while the other half showed either stability or decline in functioning. Functional improvement was associated with improved processing speed and visual memory, as well as improvement in clinical symptoms over the follow-up period. In contrast, patients who did not improve functionally showed stable clinical symptoms and cognitive performance over time. CONCLUSIONS: Although the degree of neurocognitive deficit at baseline in UHR patients does not predict psychosocial outcome, the course of neurocognitive change over the first 8 months of follow-up does differentiate patients with good and poor functional outcomes.
Authors: Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton Journal: Schizophr Res Date: 2004-12-15 Impact factor: 4.939
Authors: K H Nuechterlein; M E Dawson; M Gitlin; J Ventura; M J Goldstein; K S Snyder; C M Yee; J Mintz Journal: Schizophr Bull Date: 1992 Impact factor: 9.306
Authors: S J Wood; C Pantelis; T Proffitt; L J Phillips; G W Stuart; J A Buchanan; K Mahony; W Brewer; D J Smith; P D McGorry Journal: Psychol Med Date: 2003-10 Impact factor: 7.723
Authors: Vijay A Mittal; Maria Jalbrzikowski; Melita Daley; Cristina Roman; Carrie E Bearden; Tyrone D Cannon Journal: Schizophr Res Date: 2011-06-01 Impact factor: 4.939
Authors: Larry J Seidman; Anthony J Giuliano; Eric C Meyer; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Bruce K Christensen; Keith Hawkins; Robert Heaton; Richard S E Keefe; Robert Heinssen; Barbara A Cornblatt Journal: Arch Gen Psychiatry Date: 2010-06
Authors: Barbara A Cornblatt; Ricardo E Carrión; Jean Addington; Larry Seidman; Elaine F Walker; Tyronne D Cannon; Kristin S Cadenhead; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Scott W Woods; Robert Heinssen; Todd Lencz Journal: Schizophr Bull Date: 2011-11-10 Impact factor: 9.306
Authors: Vijay A Mittal; Derek J Dean; Jessica A Bernard; Joseph M Orr; Andrea Pelletier-Baldelli; Emily E Carol; Tina Gupta; Jessica Turner; Daniel R Leopold; Briana L Robustelli; Zachary B Millman Journal: Schizophr Bull Date: 2013-12-27 Impact factor: 9.306
Authors: Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy Journal: Schizophr Res Date: 2013-04-12 Impact factor: 4.939
Authors: Jimmy Choi; Cheryl M Corcoran; Joanna M Fiszdon; Michael Stevens; Daniel C Javitt; Melissa Deasy; Lawrence C Haber; Michael J Dewberry; Godfrey D Pearlson Journal: Psychiatr Rehabil J Date: 2016-08-25
Authors: Tara A Niendam; Kimberly L Ray; Ana-Maria Iosif; Tyler A Lesh; Stefania R Ashby; Pooja K Patel; Jason Smucny; Emilio Ferrer; Marjorie Solomon; J Daniel Ragland; Cameron S Carter Journal: JAMA Psychiatry Date: 2018-12-01 Impact factor: 21.596